The prevalence of plasmids responsible for resistance to aminoglycoside and ,B-lactam antibiotics and the selective pressure of these widely used antibiotics suggest that infection with Serratia marcescens resistant to both groups may become an increasingly frequent problem. This situation and the low toxic-therapeutic ratio of aminoglycoside antibiotics prompted the evaluation in our laboratory of the synergistic activity between carbenicillin and various aminoglycoside antibiotics against this organism (3) . Of the 55 clinical isolates evaluated, 21 were highly resistant to carbenicillin, with minimum bactericidal concentrations (MBCs) 2 8,000 ,ug/ml. No synergistic activity between carbenicillin and any of the three aminoglycoside antibiotics tested was demonstrated against these 21 isolates, in contrast to the synergistic effects of carbenicillin with an aminoglycoside against isolates more susceptible to carbenicillin. Clavulanic acid, a potent irreversible fl-lactamase inhibitor, has been found to reduce markedly the minimum inhibitory concentration (MIC) of f,-lactam antibiotics, including carbeniciUlin, for a wide spectrum of fi-lactamase-producing clinical isolates (7, 8) . This study was undertaken to examine the effect of clavulanic acid on synergism between carbenicillin and gentamicin against clinical isolates of S. marcescens, especially those highly resistant to carbenicillin.
Stock solutions of gentamicin and of carbenicillin in distilled water and of clavulanic acid in 0.1 M potassium phosphate buffer, pH 7.0, were kept at -20°C. Carbenicillin and clavulanic acid stock solutions were used within 1 week of prep-aration. All stock solutions were diluted in Trypticase soy broth (Baltimore Biological Laboratory) for use in susceptibility testing.
The effect of clavulanic acid on the synergistic activity of carbenicillin and gentamicin against S. marcescens was tested by the checkerboard twofold dilution method (6) . For each isolate tested, two checkerboards, one with and one without clavulanic acid, were set up in a single experiment. The final titer of Serratia was approximately 106 bacteria per ml, and the final concentration of clavulanic acid, when present, was 5,ug/ml. The MIC and MBC were as defined previously (3) .
Beta-lactamase production of the isolates was detected with a chromogenic cephalosporin, nitrocefm (2) .
Fifteen clinical isolates of S. marcescens obtained from the Clinical Microbiology Laboratory of the University of Chicago Hospitals and Clinics were studied (Table 1) . They were chosen for resistance to both carbenicillin and gentamicin from among isolates whose susceptibility to carbenicillin and gentamicin alone and in combination had been studied previously (3) . The MBCs of carbenicillin and gentamicin for all isolates were equal to or more than 250 and 12.5 ,ug/ml, respectively. To determine whether these 15 isolates represented a diversified population of S. marcescens, they were grouped into strains according to biotype and serotype (5) . There were at least 11 different strains by these criteria. Nine strains had one isolate each. The three isolates of strain R came from widely different areas of the hospital. Furthermore, the data on susceptibility to carbenicillin shown in Table 1 suggest that isolate 83040-1 differs from the other two isolates (88695 and 78854) of strain 8 were highly resistant to both carbenicillin and gentamicin (MBC of carbenicillin, 232,000 ug/ml and that of gentamicin, -200 jig/ml). The MBC of carbenicillin was 4,000 to 16,000 ,ug/ml for three other isolates which moreover were moderately resistant to gentamicin (MBC, 12.5 to 50,tg/ml). Four were moderately resistant to both carbenicillin (MBC, 250 to 500 ,ug/ml) and gentamicin (MBC, 12.5 to 25,g/ml).
The addition of clavulanic acid to carbenicillin (column 4) reduced the MIC of carbenicillin at least eightfold from the level with carbenicillin alone (column 3) for all but two isolates. One of these (75259) was the only isolate that lacked demonstrable f?-lactamase, and therefore it failed to respond to the fi-lactamase inhibitor. The /3-lactamase of the other isolate (82851) might be inhibited to a lesser degree by clavulanic acid than the enzymes of more highly protected strains (4, 7). Alternatively, this strain might be less permeable to clavulanic acid (7).
Although clavulanic acid had a dramatic effect on susceptibility to carbenicillin, the initial MICs of carbenicillin for most isolates were so high that they were lowered to clinically achievable levels (<125 ,tg/ml) for only four isolates (72332, 83040-1, 88695, and 78854). As expected, the addition of clavulanic acid alone did not alter by more than one dilution the MIC or MBC of gentamicin for any of the isolates (data not shown).
The addition of a subinhibitory concentration of carbenicillin (one-fourth the MIC of carbenicillin when in the presence of 5 iLg of clavulanic acid per ml) (column 6) had no appreciable effect on the MBC of gentamicin for all isolates but 82851 and 75259. Except for these two isolates and 83040-1 and 88695, the further addition of clavulanic acid to the carbenicillin and gentamicin (column 7) lowered the MBC of gentamicin synergistically, 4-to 128-fold (column 8). For five isolates this combination of clavulanic acid and a subinhibitory level of carbenicillin reduced the MBC of gentamicin to a clinically achievable level (s6.25 ig/ml). For three of these (73380, 72332, and 78854), the subinhibitory concentration of carbenicillin used in synergistic killing with clavulanic acid and gentamicin was also clinically achievable (<125 ,tg/ml).
For 10 of the 15 isolates tested in this study, the MBC of carbenicillin was -8,000 ,Lg/ml. In a previous study (3) , none of these ten isolates was killed synergistically by a combination of carbenicillin and gentamicin with concentrations of each equal to one-fourth of the individual ANTIMICROB. AGENTS CHEMOTHER.
MBCs. The simple addition of clavulanic'acid to an even lower concentration of carbenicillin in this study resulted in a profound decrease in the MBC of gentamicin from 4-to 128-fold in nine of these isolates. In addition, two of the other five isolates, which were killed synergistically by carbenicillin and gentamicin (3), showed at least fourfold reduction of the gentamicin MBC when clavulanic acid was added to a subinhibitory concentration of carbenicillin. Two of the remaining three isolates were unaffected by clavulanic acid in their susceptibility to carbenicillin. It is not surprising that clavulanic acid failed to enhance the synergism in these cases.
Although clavulanic acid has a profound effect on the synergistic potential of gentamicin with fi-lactam antibiotics such as carbenicillin, with only three isolates did it lower the synergistic concentrations of both carbenicillin and gentamicin to clinically attainable levels. With the other eight isolates against which clavulanic acid facilitated synergism, the initial levels of resistance were so high that, even with the profound enhancement of killing, the concentrations of both carbenicillin and gentamicin that acted synergistically were not 
